Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells $418,125.00 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Lee sold 1,115 shares of BeOne Medicines stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $375.00, for a total value of $418,125.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Tuesday, August 11th, Chan Lee sold 2,666 shares of BeOne Medicines stock. The shares were sold at an average price of $360.00, for a total value of $959,760.00.
• On Thursday, July 30th, Chan Lee sold 1,044 shares of BeOne Medicines stock. The shares were sold at an average price of $323.69, for a total value of $337,932.36.
• On Wednesday, July 8th, Chan Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $302.46, for a total value of $200,833.44.

BeOne Medicines Price Performance

NASDAQ ONC opened at $358.07 on Monday. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a market cap of $39.31 billion, a PE ratio of 63.04 and a beta of 0.61. The stock’s 50-day moving average price is $353.95 and its two-hundred day moving average price is $316.41.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. The company had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. On average, analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on ONC shares. Weiss Ratings raised shares of BeOne Medicines from a “sell (d-)” rating to a “hold (c+)” rating in a research note on Tuesday, September 22nd. Wolfe Research reiterated an “outperform” rating and set a $370.00 price target on shares of BeOne Medicines in a report on Monday, August 10th. Nomura raised BeOne Medicines to a “strong-buy” rating in a research note on Monday, July 27th. Citizens Jmp raised their price objective on BeOne Medicines from $396.00 to $405.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. Finally, Guggenheim lifted their target price on BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $404.14.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: JPMorgan raised its price target on BeOne Medicines to $445 from $425 and maintained an “overweight” rating, implying substantial upside from recent levels. This reinforces the broader Wall Street consensus, which remains “Buy.” JPMorgan raises BeOne Medicines price target
• Positive Sentiment: Investor’s Business Daily said BeOne shares are approaching potential buy points, highlighting continued momentum in BRUKINSA, the company’s blockbuster cancer drug, which generated $1.2 billion in second-quarter sales. BeOne Medicines poised to hit early buy points
• Neutral Sentiment: BeOne’s latest quarterly results exceeded expectations, with earnings of $2.05 per share versus a $1.40 consensus estimate and revenue of $1.71 billion versus $1.66 billion. Analysts expect approximately $8.81 in full-year earnings per share, although the stock’s valuation remains elevated at more than 60 times earnings.
• Negative Sentiment: Insider Xiaodong Wang sold 31,028 shares for approximately $11.3 million, reducing his direct ownership by 50%. Separately, Senior Vice President Chan Lee sold 1,115 shares for about $418,000. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which lessens—but does not eliminate—their significance as a sentiment signal. BeOne Medicines insider sales

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors and hedge funds have recently modified their holdings of the stock. Global Retirement Partners LLC boosted its position in BeOne Medicines by 1,051.7% during the fourth quarter. Global Retirement Partners LLC now owns 334 shares of the company’s stock valued at $101,000 after purchasing an additional 305 shares during the last quarter. Parallel Advisors LLC increased its position in BeOne Medicines by 24.0% in the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock worth $104,000 after purchasing an additional 68 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in BeOne Medicines by 16.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock worth $110,000 after purchasing an additional 52 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of BeOne Medicines during the 1st quarter worth about $201,000. Finally, Empowered Funds LLC purchased a new stake in shares of BeOne Medicines during the 1st quarter worth about $201,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.

Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers.